Golden has been acquired by ComplyAdvantage.Read about it here ⟶

‌

US Patent 10047053 Deuterated CFTR potentiators

Patent 10047053 was granted and assigned to Vertex Pharmaceuticals (Europe) Limited on August, 2018 by the United States Patent and Trademark Office.

Overview Structured Data Issues Contributors Activity

Is a

Patent

Patent attributes

Patent Applicant

‌

Vertex Pharmaceuticals (Europe) Limited

Current Assignee

‌

Vertex Pharmaceuticals (Europe) Limited

Patent Jurisdiction

United States Patent and Trademark Office

Patent Number

10047053

Date of Patent

August 14, 2018

Patent Application Number

15827792

Date Filed

November 30, 2017

Patent Citations Received

‌

US Patent 12024491 Processes for making modulators of cystic fibrosis transmembrane conductance regulator

‌

US Patent 10759721 Deuterated CFTR potentiators

‌

US Patent 10894773 Deuterated CFTR potentiators

‌

US Patent 11708331 Processes for making modulators of cystic fibrosis transmembrane conductance regulator

‌

US Patent 10479766 Deuterated CFTR potentiators

‌

US Patent 10738036 Deuterated CFTR modulators

Patent Primary Examiner

‌

Heidi Reese

Patent abstract

This invention relates to compounds of Formula I:

Timeline

No Timeline data yet.

Further Resources

Title

Author

Link

Type

Date

No Further Resources data yet.

References

Find more entities like US Patent 10047053 Deuterated CFTR potentiators

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.

Open Query Tool

Access by API